EGFR 돌연변이가 있는 폐의 육종양 암종에서의 Gefitinib을 사용하여 치료한 2예
Gefitinib Treatment for Pulmonary Sarcomatoid Carcinoma Driven by an EGFR Mutation: Two Cases
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
저자들은 EGFR 돌연변이가 있는 폐의 육종양 암종에서 EGFR 표적치료제인 gefitinib을 사용하여 치료한 2예를 경험하였고, 부분관해(partial response) 이상의 반응을 나타내었다. 이에 증례고찰과 함께 보고하는 바이다.
Abstract
Sarcomatoid carcinoma of the lung is defined as a group of poorly differentiated non-small cell carcinomas that contain a component of sarcoma or a sarcoma-like element. Most sarcomatoid carcinomas are known to have a poor prognosis. We describe a 45-year-old female never smoker and 49-year-old female never smoker with sarcomatoid carcinomas of the lung that expressed a specific EGFR mutation: microdeletion of exon 19. Their cancers progressed rapidly, despite appropriate conventional chemotherapy. After they took the EGFR-targeted agent gefitinib, there was a dramatic reduction in tumor size. Sarcomatoid carcinoma of the lung is a rare cancer whose pathogenesis is not well understood. According to these cases, the EGFR mutation could be a driver mutation and the potential therapeutic target of EGFR-targeted agents for sarcomatoid carcinoma in lung cancer patients, especially never smokers.
참고문헌 (10)
- Brambilla E, "The new World Health Organization classification of lung tumours", Eur Respir J, 18, pp.1059~1068 (2001)
- Pelosi G, "Review article : pulmonary sarcomatoid carcinomas : a practical overview", Int J Surg Pathol, 18, pp.103~120 (2010)
- Ushiki A, "Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung : response to gefitinib and clinical outcome", Jpn J Clin Oncol, 39, pp.267~270 (2009)
- Maemondo M, "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR", N Engl J Med, 362, pp.2380~2388 (2010)
- Paez JG, "EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy", Science, 304, pp.1497~1500 (2004)
- Kaira K, "Pulmonary pleomorphic carcinoma : a clinicopathological study including EGFR mutation analysis", J Thorac Oncol, 5, pp.460~465 (2010)
- Italiano A, "EGFR and KRAS status of primary sarcomatoid carcinomas of the lung : implications for anti-EGFR treatment of a rare lung malignancy", Int J Cancer, 125, pp.2479~2482 (2009)
- Lee S, "Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy", J Cancer Res Clin Oncol, 137, pp.1203~1211 (2011)
- Pao W, "Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain", PLoS Med, 2, pp.73~ (2005)
- Sequist LV, "Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors", Sci Transl Med, 3, pp.75~ (2011)